All Stories

  1. Percutaneous Coronary Intervention Associated with a Higher Risk of Hypoxemia and COVID-19 Severity
  2. The Immunogenic Potential of PCSK9 Peptide Vaccine in Mice
  3. Impact of vitamin D receptor polymorphisms in selected metabolic disorders
  4. Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials
  5. Dyslipidemia treatment and attainment of LDL-cholesterol treatment goals in patients participating in the Managed Care for Acute Myocardial Infarction Survivors program
  6. Age-Related Differences in the Role of Risk Factors for Ischemic Stroke
  7. De-escalation of antiplatelet therapy in patients with coronary artery disease: Time to change our strategy?
  8. Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network
  9. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)
  10. On the Need for a Paradigm Change in the Valuation of Concrete with Waste Materials Based on the Example of Concrete with Crumb Rubber
  11. Efficacy and safety of bempedoic acid in women with hypercholesterolemia: Pooled analyses from phase 3 trials
  12. Higher Plasma Levels of Valerate Produced by Gut Microbiota May Have a Beneficial Impact on Renal Function
  13. In Reply: ACEI and ARB — Each Unique RAAS Inhibitors
  14. Glucometabolic Perturbations in Type 2 Diabetes Mellitus and Coronavirus Disease 2019: Causes, Consequences, and How to Counter Them Using Novel Antidiabetic Drugs – The CAPISCO International Expert ...
  15. Which Statin is Best for the Kidneys?
  16. Coffee or tea: Anti-inflammatory properties in the context of atherosclerotic cardiovascular disease prevention
  17. Can We Use mTOR Inhibitors for COVID-19 Therapy?
  18. The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990–2019: Findings from the Global Burden of Disease Study 2019
  19. Global, regional, and national burden of colorectal cancer and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  20. Prognostic Impact of Hybrid Comprehensive Telerehabilitation Regarding Diastolic Dysfunction in Patients with Heart Failure with Reduced Ejection Fraction—Subanalysis of the TELEREH-HF Randomized Clinical Trial
  21. Investigation of the Effect of Curcumin on Protein Targets in NAFLD Using Bioinformatic Analysis
  22. Contemporary Management of Dyslipidemia
  23. Which patients at risk of cardiovascular disease might benefit the most from inclisiran? – The expert opinion of the Polish experts. The compromise between EBM and possibilities in healthcare.
  24. The detrimental impact of elevated Ferritin to Iron ratio on in-hospital prognosis of patients with COVID-19
  25. Global, regional, and national burden of diseases and injuries for adults 70 years and older: systematic analysis for the Global Burden of Disease 2019 Study
  26. Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications
  27. Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials
  28. Heart Failure Risk Predictions and Prognostic Factors in Adults With Congenital Heart Diseases
  29. Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study
  30. Homozygous familial hypercholesterolaemia: shedding new light on a rare but deadly condition
  31. Causes, clinical findings and therapeutic options in chylomicronemia syndrome, a special form of hypertriglyceridemia
  32. Protective role of nutraceuticals against myocarditis
  33. Relationship between Low-Density Lipoprotein Cholesterol, Lipid Lowering Agents and the Risk of Stroke: A meta-analysis of Observational studies (n=355,591) and Randomized Controlled Trials (n=165,988).
  34. Discordance between LDL-C and Apolipoprotein B Levels and Its Association with Renal Dysfunction: Insights from a Population-Based Study
  35. Effectiveness of Curcumin on Outcomes of Hospitalized COVID-19 Patients: A Systematic Review of Clinical Trials
  36. Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials
  37. The Association between Coffee and Caffeine Consumption and Renal Function: Insight from Individual-Level Data, Mendelian Randomization, and Meta-Analysis
  38. Implications of the 2021 ESC Cardiovascular Risk Classification among 283,000 European Immigrants Living in a Low-Risk Region: A Population-Based Analysis in Catalonia
  39. Sleep Duration May Not Have Any Effect on The Risk of Stroke: Insights from Mendelian Randomization and Prospective Cohort Studies
  40. Extreme cardiovascular risk—do we need a new risk category?
  41. Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study
  42. PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
  43. A systematic review and meta-analysis on the effects of statins on pregnancy outcomes
  44. Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE
  45. COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection
  46. Risk Assessment and Clinical Management of Children and Adolescents with Heterozygous Familial Hypercholesterolaemia. A Position Paper of the Associations of Preventive Pediatrics of Serbia, Mighty Medic and International Lipid Expert Panel
  47. The International Lipid Expert Panel (ILEP)—the role of ‘optimal’ collaboration in the effective diagnosis and treatment of lipid disorders
  48. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study
  49. Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study
  50. Improved COVID-19 Outcomes following Statin Therapy: An Updated Systematic Review and Meta-analysis
  51. Harnessing polyphenol power by targeting eNOS for vascular diseases
  52. Clinical Features of Familial Hypercholesterolemia in Children and Adults in EAS-FHSC Regional Center for Rare Diseases in Poland
  53. The Yin and Yang of High-density Lipoprotein and Atherosclerotic Cardiovascular Disease: Focusing on Functionality and Cholesterol Efflux to Reframe the HDL Hypothesis
  54. Global, regional, and national sex differences in the global burden of tuberculosis by HIV status
  55. Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry
  56. The interaction of Helicobacter pylori with cancer immunomodulatory stromal cells: New insight into gastric cancer pathogenesis
  57. Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice
  58. Dyslipidemia Management in Patients with Coronary Artery Disease. Data from the POLASPIRE Survey
  59. Compositional and functional properties of high-density lipoproteins in relation to coronary in-stent restenosis
  60. Are risk-based LDL-c goals achieved in primary and secondary care in central and Eastern Europe? comparison with other Europe regions from the DA VINCI observational study
  61. Factors and Prognostic Significance of Impaired Exercise Tolerance in Women over 40 with Arterial Hypertension
  62. Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors - analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studies.
  63. Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies
  64. Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations
  65. Is COVID-19 Another Case of Obesity Paradox? - Results from An International Ecological Study on behalf of the REPROGRAM Consortium Obesity
  66. COVID-19 and cardiovascular complications – the preliminary results of the LATE-COVID study
  67. Serum anti-inflammatory and inflammatory markers have no causal impact on telomere length: a Mendelian randomization study
  68. Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications
  69. Targeting AMPK by Statins: A Potential Therapeutic Approach
  70. Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force
  71. Antiarrhythmic effect of 9-week hybrid cardiac telerehabilitation - subanalysis of the TELEREHabilitation in Heart Failure patients - TELEREH-HF randomized clinical trial
  72. Omega-6 fatty acids and the Risk of Cardiovascular Disease: Insights from a Systematic Review and Meta-Analysis of Randomized Controlled Trials and a Mendelian Randomization Study.
  73. Foam Cells as Therapeutic Targets in Atherosclerosis with a Focus on the Regulatory Roles of Non-Coding RNAs
  74. Α higher ratio of serum uric acid to serum creatinine could predict the risk of total and cause specific mortality- insight from a US national survey
  75. Role of confirmed and potential predictors of an unfavorable outcome in heart failure in everyday clinical practice
  76. Renal Denervation for Uncontrolled and Resistant Hypertension: Systematic Review and Network Meta-Analysis of Randomized Trials
  77. Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel
  78. An aetiology‐based subanalysis of the Telerehabilitation in Heart Failure Patients (TELEREH‐HF) trial
  79. Effects of statins on mitochondrial pathways
  80. Drucebo effect – the challenge we should all definitely face!
  81. Lipid-lowering therapies: Better together
  82. Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants
  83. Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study
  84. New trends in the pharmacological intervention of PPARs in obesity: Role of natural and synthetic compounds_
  85. Longer sleep duration may negatively affect renal function
  86. Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient Therapeutic Targets to Treat COVID-19
  87. Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic
  88. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis
  89. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
  90. Cholesterol in Relation to COVID-19: Should We Care about It?
  91. Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017
  92. Epigenetics in atherosclerosis: key features and therapeutic implications
  93. Anti-inflammatory Action of Statins in Cardiovascular Disease: the Role of Inflammasome and Toll-Like Receptor Pathways
  94. Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017
  95. Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017
  96. Clinical factors related to successful or unsuccessful cardioversion in the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE‐AF) randomized trial
  97. An overview of statin-induced myopathy and perspectives for the future
  98. Association between rs2107595 HDAC9 gene polymorphism and advanced carotid atherosclerosis in the Slovenian cohort
  99. Egg Intake: Getting the Balance Right!
  100. Adverse impact of egg consumption on fatty liver is partially explained by cardiometabolic risk factors: A population-based study
  101. Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3
  102. Effect of Evolocumab on Non‐High‐Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies
  103. Changes in disease burden in Poland between 1990–2017 in comparison with other Central European countries: A systematic analysis for the Global Burden of Disease Study 2017
  104. Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels
  105. A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS EVALUATING RENAL DENERVATION FOR UNCONTROLLED AND RESISTANT HYPERTENSION
  106. Associations of serum uric acid with total and cause-specific mortality: Findings from individuals and pooling prospective studies
  107. BEMPEDOIC ACID EFFICACY AND SAFETY IN HIGH CVD RISK PATIENTS TREATED WITH OR WITHOUT EZETIMIBE: POOLED ANALYSIS OF 4 PHASE 3 CLINICAL TRIALS
  108. EFFICACY AND SAFETY OF ALIROCUMAB IN A REAL-LIFE SETTING IN PATIENTS WITH OR WITHOUT FAMILIAL HYPERCHOLESTEROLEMIA: THE ODYSSEY APPRISE STUDY
  109. Effects of a 9-Week Hybrid Comprehensive Telerehabilitation Program on Long-term Outcomes in Patients With Heart Failure
  110. FACTORS THAT INFLUENCE BEMPEDOIC ACID-MEDIATED REDUCTIONS IN HIGH-SENSITIVITY C-REACTIVE PROTEIN: ANALYSIS OF POOLED PATIENT-LEVEL DATA FROM PHASE 3 CLINICAL TRIALS
  111. Incretins and microRNAs: Interactions and physiological relevance
  112. High‐Sensitivity C‐Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study
  113. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  114. LCZ696 (sacubitril/valsartan) for patients with heart failure
  115. Apolipoprotein B/Apolipoprotein A-I Ratio Is a Better Predictor of Cancer Mortality Compared with C-Reactive Protein: Results from Two Multi-Ethnic US Populations
  116. Epidemiology of facial fractures: incidence, prevalence and years lived with disability estimates from the Global Burden of Disease 2017 study
  117. 2020 Guidelines of the Polish Society of Laboratory Diagnostics (PSLD) and the Polish Lipid Association (PoLA) on laboratory diagnostics of lipid metabolism disorders
  118. Effects of immunisation against PCSK9 in mice bearing melanoma
  119. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved Abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2
  120. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic
  121. Low-carbohydrate diet: forget restriction, replace with balance!
  122. Impact of serum 25-hydroxyvitamin D 25(OH) on telomere attrition: A Mendelian Randomization study
  123. Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
  124. Effect of Pycnogenol on Blood Pressure: Findings From a PRISMA Compliant Systematic Review and Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled, Clinical Studies
  125. Ca2+ Flux: Searching for a Role in Efferocytosis of Apoptotic Cells in Atherosclerosis
  126. Statins and Lp(a): do not make perfect the enemy of excellent
  127. Altilix® Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study
  128. Association of Serum PCSK9 Levels with Antibiotic Resistance and Severity of Disease in Patients with Bacterial Infections Admitted to Intensive Care Units
  129. Arterial Stiffness and Indices of Left Ventricular Diastolic Dysfunction in Patients with Embolic Stroke of Undetermined Etiology
  130. A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome
  131. Genetic testing in familial hypercholesterolaemia: What does it add?
  132. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease
  133. Modulation of microRNAs by aspirin in cardiovascular disease
  134. Methotrexate for Cardiovascular Risk Reduction: The Right Choice?
  135. A review of gene- and cell-based therapies for familial hypercholesterolemia
  136. Macrophage plasticity, polarization and function in response to curcumin, a diet-derived polyphenol, as an immunomodulatory agent
  137. A higher flavonoid intake is associated with less likelihood of nonalcoholic fatty liver disease: results from a multiethnic study
  138. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials
  139. Role of Geriatric Syndromes in the Management of Atrial Fibrillation in Older Adults: A Narrative Review
  140. Dietary natural products as emerging lipoprotein(a)‐lowering agents
  141. What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcomes trials?
  142. Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes – Data from the TERCET registry with 19,287 patients
  143. A systematic review and meta-analysis of clinical trials investigating the effects of flaxseed supplementation on plasma C-reactive protein concentrations
  144. High-Density Lipoprotein Components and Functionality in Cancer: State-of-the-Art
  145. Global, Regional, and Country-Specific Lifetime Risks of Stroke, 1990 and 2016
  146. Oxidative Stress in Women Treated with Atosiban for Impending Preterm Birth
  147. Link between plasma trans-fatty acid and fatty liver is moderated by adiposity
  148. Consumption of dairy product and its association with total and cause specific mortality – A population-based cohort study and meta-analysis
  149. Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score
  150. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials
  151. MicroRNAs: Novel Molecular Targets and Response Modulators of Statin Therapy
  152. Natural products for targeted therapy in precision medicine
  153. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
  154. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease ...
  155. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  156. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  157. Measuring progress of the health-related Sustainable Development Goals for 195 countries
  158. Associations between risk of overall mortality, cause-specific mortality and level of inflammatory factors with extremely low and high high-density lipoprotein cholesterol levels among American adults
  159. Ideal cardiovascular health associated with fatty liver: Results from a multi-ethnic survey
  160. Impact of Body Mass Index on Outcomes in the Edoxaban Versus Warfarin Therapy Groups in Patients Undergoing Cardioversion of Atrial Fibrillation (From ENSURE-AF)
  161. Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017
  162. Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017
  163. Phytol: A review of biomedical activities
  164. Effect of fenofibrate on plasma apolipoprotein C-III levels: a systematic review and meta-analysis of randomised placebo-controlled trials
  165. Inverse association between serum antioxidant levels and inflammatory markers is moderated by adiposity: a report based on a large representative population sample of American adults
  166. A higher ratio of refined grain to whole grain is associated with a greater likelihood of chronic kidney disease: a population-based study
  167. Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions
  168. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
  169. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
  170. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
  171. The Yin and Yang of carbon nanomaterials in atherosclerosis
  172. Application of nanotechnology to improve the therapeutic benefits of statins
  173. Effect of omega-3 supplements on plasma apolipoprotein C-III concentrations: a systematic review and meta-analysis of randomized controlled trials
  174. Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations
  175. Adiposity mediates the association between whole grain consumption, glucose homeostasis and insulin resistance: findings from the US NHANES
  176. Effect of statins on toll-like receptors: a new insight to pleiotropic effects
  177. Dietary inflammatory index and cardiometabolic risk in US adults
  178. PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?
  179. Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study
  180. Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey
  181. Subclinical hypothyroidism and the development of heart failure: an overview of risk and effects on cardiac function
  182. Monocyte-to-HDL-cholesterol ratio as a prognostic marker in cardiovascular diseases
  183. Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study
  184. Alcohol use and attributable disease burden in 195
  185. Modulation of heat shock proteins by statins
  186. Incidence of familial hypercholesterolemia in patients from the tercet registry
  187. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an “FCS score”
  188. Novel Therapeutic Targets for Managing Dyslipidemia
  189. The optimal time of day for statin administration
  190. Serum lipophilic antioxidants levels are associated with leucocyte telomere length among US adults
  191. Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines
  192. Decompensated Heart Failure and Renal Failure: What Is the Current Evidence?
  193. High density lipoprotein cholesterol and cancer: Marker or causative?
  194. The Role of Nutraceuticals in Statin Intolerant Patients
  195. Impact of fibrates on circulating cystatin C levels: a systematic review and meta-analysis of clinical trials
  196. Leptin, cardiovascular diseases and type 2 diabetes mellitus
  197. Measuring performance_Healthcare Access_Quality Index for 195 countries and territories
  198. Effect of fibrates on glycemic parameters: A systematic review and meta-analysis of randomized placebo-controlled trials
  199. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease
  200. Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry
  201. From meta-analysis to Cochrane reviews
  202. Higher dietary acid load is associated with higher likelihood of peripheral arterial disease among American adults
  203. Phase 3 Evaluation of Bempedoic Acid Added to Ezetimibe in Patients with Elevated LDL-cholesterol Receiving No Greater Than Low Dose Statins: CLEAR Tranquility
  204. PCSK9 genetic variants, life-long lowering of LDL-cholesterol and cognition: a large-scale Mendelian randomization study
  205. Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?
  206. Effect of Metformin on Plasma Fibrinogen Concentrations: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
  207. Resveratrol effect on patients with non-alcoholic fatty liver disease: A matter of dose and treatment length
  208. Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995–2015
  209. Trends in future health financing and coverage: future health spending and universal health coverage in 188 countries, 2016–40
  210. Effect of statin therapy on plasma apolipoprotein CIII concentrations: A systematic review and meta-analysis of randomized controlled trials
  211. Statin Intolerance
  212. The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review
  213. The impact of nuts consumption on glucose/insulin homeostasis and inflammation markers mediated by adiposity factors among American adults
  214. Polyphenols: Potential Use in the Prevention and Treatment of Cardiovascular Diseases
  215. Prosarcopenic Effects of Statins May Limit Their Effectiveness in Patients with Heart Failure
  216. Botanicals and phytochemicals active on cognitive decline: The clinical evidence
  217. Evaluation of a dimeric-cRGD peptide for targeted PET-CT imaging of peripheral angiogenesis in diabetic mice
  218. Novel drugs for heart rate control in heart failure
  219. Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants
  220. Association between plasma trans fatty acids concentrations and leucocyte telomere length in US adults
  221. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland
  222. The link between insulin resistance parameters and serum uric acid is mediated by adiposity
  223. Bleeding in advanced CKD patients on antithrombotic medication – A critical appraisal
  224. IMPACT OF BODY MASS INDEX AND OBESITY ON CLINICAL OUTCOMES IN THE EDOXABAN VERSUS WARFARIN IN SUBJECTS UNDERGOING CARDIOVERSION OF ATRIAL FIBRILLATION (ENSURE-AF) RANDOMIZED TRIAL
  225. Lipid accumulation product and triglycerides/glucose index are useful predictors of insulin resistance
  226. Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  227. Effects of coenzyme Q10 supplementation on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials
  228. Management of Statin Intolerance in 2018: Still More Questions Than Answers
  229. Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview
  230. Complications of Diabetes 2017
  231. Effect of magnesium supplements on serum C-reactive protein: a systematic review and meta-analysis
  232. Effect of soy isoflavone supplementation on plasma lipoprotein(a) concentrations: A meta-analysis
  233. HDL functionality in familial hypercholesterolemia: effects of treatment modalities and pharmacological interventions
  234. Hypercholesterolaemia – practical information for non-specialists
  235. Natural approaches in metabolic syndrome management
  236. Prevalence of childhood and adolescent overweight and obesity in Asian countries: a systematic review and meta-analysis
  237. Association Between Plasma Trans-Fatty Acid Concentrations and Measures of Glucose Homeostasis and Cardiovascular Risk Factors in Adults in NHANES 1999-2000
  238. Adhering to the principles of clinical pharmacology - the correct fixed combinations of antihypertensive drugs
  239. Emerging enzymatic targets controlling angiogenesis in cancer: preclinical evidence and potential clinical applications
  240. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults
  241. Dietary patterns, plasma vitamins and Trans fatty acids are associated with peripheral artery disease
  242. HDL functionality in type 1 diabetes
  243. Recent perspectives on the role of nutraceuticals as cholesterol-lowering agents
  244. Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
  245. The impact of argan oil on plasma lipids in humans: Systematic review and meta-analysis of randomized controlled trials
  246. The effects of cinnamon supplementation on blood lipid concentrations: A systematic review and meta-analysis
  247. The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study
  248. Dietary food patterns and glucose/insulin homeostasis: a cross-sectional study involving 24,182 adult Americans
  249. The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis
  250. Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials
  251. C-reactive Protein Is Associated With Prevalence of the Metabolic Syndrome, Hypertension, and Diabetes Mellitus in US Adults
  252. Telomere attrition, kidney function, and prevalent chronic kidney disease in the United States
  253. Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-α concentrations: A systematic review and meta-analysis of controlled trials
  254. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
  255. Optimizing Cholesterol Treatment in Patients With Muscle Complaints
  256. Does coffee consumption alter plasma lipoprotein(a) concentrations? A systematic review
  257. The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction
  258. Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?
  259. Usefulness of atherogenic dyslipidemia index to assess the cardiovascular risk of primary care patients – Results from lipidogram 2004 and lipidogram 2006 studies
  260. Lipids profile and efficacy of treatment of dyslipidemia in primary care in Poland. Results of lipidogram 5 years study (2004–2010)
  261. The assessment of selected markers of cardiac dysfunction in the analysis of cardiovascular risk in dialysis patients
  262. The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials
  263. Curcumin: A Naturally Occurring Modulator of Adipokines in Diabetes
  264. Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis
  265. Lipoprotein(a): A missing culprit in the management of athero-thrombosis?
  266. PCSK9 and infection: A potentially useful or dangerous association?
  267. Hypertension - Current Natural Strategies to Lower Blood Pressure
  268. Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia
  269. The Use of Plant Sterols and Stanols as Lipid-Lowering Agents in Cardiovascular Disease
  270. Editorial: Natural Products as the Integral Part of the Therapy?
  271. HDL abnormalities in familial hypercholesterolemia: Focus on biological functions
  272. Isolated diastolic hypertension and incident heart failure in community-dwelling older adults: Insights from the Cardiovascular Health Study
  273. Statins, haemostatic factors and thrombotic risk
  274. Corrigendum to “Systolic–diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the cardiovascular health study” [Int. J. Cardiol. 235 (2017) 11–16]
  275. Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis
  276. Blood Pressure, Antihypertensive Polypharmacy, Frailty, and Risk for Serious Fall Injuries Among Older Treated Adults With HypertensionNovelty and Significance
  277. Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal Diseases
  278. Synthesis, Chemical Characterization and Multiscale Biological Evaluation of a Dimeric-cRGD Peptide for Targeted Imaging of α V β 3 Integrin Activity
  279. Telomere Length Is Associated With Cardiometabolic Factors in US Adults
  280. Response letter: Management of statin-induced myopathies: Much demands and still (almost) empty hands!
  281. PCSK9 and diabetes: is there a link?
  282. Regulation of PCSK9 by nutraceuticals
  283. The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis
  284. Effects of selected dietary constituents on high-sensitivity C-reactive protein levels in U.S. adults
  285. MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?
  286. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
  287. Hydrophilic vs lipophilic statins in coronary artery disease: A meta-analysis of randomized controlled trials
  288. Relationship between long noncoding RNAs and physiological risk factors of cardiovascular disease
  289. Effects of curcumin on HDL functionality
  290. Systolic–diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the Cardiovascular Health Study
  291. Accuracy of low-density lipoprotein cholesterol estimation at very low levels
  292. The role of nutraceuticals in the prevention of cardiovascular disease
  293. PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk
  294. The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients
  295. Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials
  296. Raloxifene Lowers Plasma Lipoprotein(a) Concentrations: a Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials
  297. Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction
  298. HYDROPHILIC VERSUS LIPOPHILIC STATINS IN CORONARY ARTERY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
  299. EDOXABAN THERAPY INCREASES TREATMENT SATISFACTION AND REDUCES UTILIZATION OF HEALTH CARE RESOURCES: AN ANALYSIS FROM THE EDOXABAN VERSUS WARFARIN IN SUBJECTS UNDERGOING CARDIOVERSION OF ATRIAL FIBRILLATION (ENSURE-AF) STUDY
  300. Are two drugs better than one? A review of combination therapies for hypertension
  301. The potential role of mitochondrial ATP synthase inhibitory factor 1 (IF1) in coronary heart disease: a literature review
  302. Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials
  303. Mineral and vitamins consumption is associated with longer telomeres among US adults
  304. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence
  305. Intensive LDL-cholesterol lowering therapy and neurocognitive function
  306. Novel approaches toward the generation of bioscaffolds as a potential therapy in cardiovascular tissue engineering
  307. Wytyczne PTL/KLRwP/PTK dotyczące postępowania w zaburzeniach lipidowych dla lekarzy rodzinnych 2016
  308. Evaluating bempedoic acid for the treatment of hyperlipidaemia
  309. Impact of Statin Therapy on Plasma MMP-3, MMP-9, and TIMP-1 Concentrations: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
  310. High-Density Lipoprotein and Low-Density Lipoprotein Subfractions in Patients with Chronic Kidney Disease
  311. Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?
  312. Association between telomere length and complete blood count in US adults
  313. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel
  314. Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9
  315. Physical Exercise and DNA Injury
  316. PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016
  317. The association of telomere length and serum 25-hydroxyvitamin D levels in US adults: the National Health and Nutrition Examination Survey
  318. Vitamin D deficiency and non-lipid biomarkers of cardiovascular risk
  319. PCSK9 inhibitors in sepsis: a new potential indication?
  320. Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?
  321. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration
  322. Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement
  323. D-003 (Saccharum officinarum): The forgotten lipid-lowering agent
  324. Effects of pentoxifylline on inflammatory markers and blood pressure
  325. Lipid-modifying effects of nutraceuticals: An evidence-based approach
  326. Differences in biochemical and genetic biomarkers in patients with heart failure of various etiologies
  327. What is the association of lipid levels and incident stroke?
  328. Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms
  329. Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm
  330. Polypills for the prevention of Cardiovascular diseases
  331. Curcumin: An effective adjunct in patients with statin-associated muscle symptoms?
  332. Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease
  333. A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients
  334. Aortic valve stenosis: what do people know? A heart valve disease awareness survey of over 8,800 people aged 60 or over
  335. A systematic review and meta-analysis comparing the effects of statins and fibrates on plasma lipoprotein(a) levels
  336. Can the effects of gender, menopause and ageing on lipid levels be differentiated?
  337. A systematic review and meta-analysis of the impact of Spirulina supplementation on plasma lipid concentrations
  338. Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
  339. Complex relationship of obesity and obesity paradox in heart failure – higher risk of developing heart failure and better outcomes in established heart failure
  340. Effects of Quercetin on Blood Pressure: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
  341. Bioresorbable scaffold — A magic bullet for the treatment of coronary artery disease?
  342. IMPROVE-IT
  343. Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases – Some answers and still many questions
  344. Editorial: MicroRNA-33 Inhibition: A Potential Adjunct to Statin Therapy?
  345. Expert opinion: the therapeutic challenges faced by statin intolerance
  346. Effects of flaxseed supplements on blood pressure: A systematic review and meta-analysis of controlled clinical trial
  347. Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases
  348. Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials
  349. Lipoprotein (a)—We Know So Much Yet Still Have Much to Learn …
  350. THE EFFECT OF QUERCETIN ON BLOOD PRESSURE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
  351. Rozpowszechnienie zaburzeń lipidowych w Polsce. Wyniki badania NATPOL 2011.
  352. Erratum to: Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study
  353. The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease
  354. Healthy lifestyle factors and incident heart disease and mortality in candidates for primary prevention with statin therapy
  355. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT
  356. Discussion around statin discontinuation in older adults and patients with wasting diseases
  357. Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study
  358. Predictive Value for Galectin 3 and Cardiotrophin 1 in Hemodialysis Patients
  359. Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate
  360. Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials
  361. Effect of garlic on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled clinical trials
  362. Exosomes as nanocarriers for siRNA delivery: paradigms and challenges
  363. Complications of Diabetes 2016
  364. Evaluation of medical and psychological parameters of quality of life in supraventricular tachyarrhythmia children. A comparison with healthy children
  365. Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis
  366. Molecular mechanisms of statin intolerance
  367. Subfractions of high-density lipoprotein (HDL) and dysfunctional HDL in chronic kidney disease patients
  368. The impact of statin therapy on plasma levels of von Willebrand factor antigen
  369. Sex-dependent differences in obesity indices and inflammatory markers in non-diabetic obese patients
  370. Lipids, blood pressure and kidney update 2015
  371. Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options
  372. Familial hypercholesterolaemia: A global call to arms
  373. Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials
  374. Impact of anemia treatment with methoxy polyethylene glycol-epoetin beta on polymorphonuclear cells apoptosis in predialysis patients with chronic kidney disease
  375. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies
  376. An evaluation of RVX-208 for the treatment of atherosclerosis
  377. Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials
  378. Effects of supplementation with green tea catechins on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials
  379. Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: The Very Large Database of Lipids-4 (VLDL-4) study
  380. Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients
  381. Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Non–High-Density Lipoprotein Cholesterol
  382. Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials
  383. Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study
  384. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease
  385. A systematic review and meta-analysis of the impact of spirulina supplementation on plasma lipid concentrations
  386. Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials
  387. Markers of increased cardiovascular risk in elderly patients with chronic kidney disease: A preliminary study
  388. Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials
  389. Strength-endurance training may promote pro-atherogenic changes in lipoprotein profile of adolescent rowers
  390. Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension
  391. Is Blood Pressure Control for Stroke Prevention the Correct Goal?
  392. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors — Results from a systematic review and meta-analysis of randomized controlled trials
  393. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations
  394. Sudden cardiac death in CKD patients
  395. The Multi-Biomarker Approach for Heart Failure in Patients with Hypertension
  396. Lipids, blood pressure and kidney update 2014
  397. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
  398. Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge
  399. Biomarkers and Echocardiographic Predictors of Myocardial Dysfunction in Patients with Hypertension
  400. Renalase is Removed by Kidneys and During Dialysis – Excess Related to CKD Complications?
  401. In reply—Coenzyme Q10 and Statin-Induced Myopathy
  402. Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study
  403. Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease
  404. Combination Therapy In Dyslipidemia
  405. Conclusions and Take Home Message
  406. Complications of Diabetes
  407. Statins and Fibrates: Should They Be Recommended?
  408. Letter to the Editor Dysfunctional high-density lipoprotein: not only quantity but first of all quality?
  409. Wpływ statyn na majaczenie w następstwie operacji kardiochirurgicznych – dowody z piśmiennictwa
  410. Analysis of vitamin D levels in patients with and without statin-associated myalgia — A systematic review and meta-analysis of 7 studies with 2420 patients
  411. Association between statin use and plasma D-dimer levels
  412. Effects of Coenzyme Q10 on Statin-Induced Myopathy
  413. Systematic review/Meta-analysis Lipid profile and glucose changes after supplementation with astaxanthin: a systematic review and meta-analysis of randomized controlled trials
  414. Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel
  415. The influence of hypoxic physical activity on cfDNA as a new marker of vascular inflammation
  416. Club 35 Poster session 3: Friday 5 December 2014, 08:30-18:00 * Location: Poster area
  417. Effects of Established Hypolipidemic Drugs on HDL Concentration, Subclass Distribution, and Function
  418. ETC-1002: A future option for lipid disorders?
  419. Contrasting Cholesterol Management Guidelines for Adults with CKD
  420. Red blood cell transfusion is a determinant of neurological complications after cardiac surgery
  421. Association of systolic blood pressure levels with cardiovascular events and all-cause mortality among older adults taking antihypertensive medication
  422. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient
  423. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline
  424. Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation
  425. Atherogenic Versus Non-atherogenic Lipoprotein Profiles in Healthy Individuals. Is There a Need to Change Our Approach to Diagnosing Dyslipidemia?
  426. Can We Change the Functionality of HDL Cholesterol with Nonpharmacological and Pharmacological Agents?
  427. Subfractions and Subpopulations of HDL: An Update
  428. Editorial (Thematic Issue: Current Research, Knowledge and Controversies on High Density Lipoprotein)
  429. Pre-CKD- Do we Need Another Hero?
  430. Patients with Prehypertension – Do we have Enough Evidence to Treat them?
  431. Editorial (Thematic Issue: The Changing Face of Metabolic Syndrome and its Components in the Light of Current Knowledge)
  432. Influence of exercise training on T-wave alternans assessed during exercise test in heart failure patients
  433. Proprotein Convertase Subtilisin/Kexin 9 Inhibitors
  434. Statins and New-Onset Diabetes
  435. Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease
  436. Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality
  437. Should low high-density lipoprotein cholesterol (HDL-C) be treated?
  438. The effect of timing of cardiac catheterization on acute kidney injury after cardiac surgery is influenced by the type of operation
  439. Novel anti-obesity drugs and plasma lipids
  440. Bedside Tool for Predicting the Risk of Postoperative Atrial Fibrillation After Cardiac Surgery: The POAF Score
  441. Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum
  442. Lipid, blood pressure and kidney update 2013
  443. Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level
  444. Obesity indices and inflammatory markers in obese non-diabetic normo- and hypertensive patients: a comparative pilot study
  445. Dysfunctional HDL: the journey from savior to slayer
  446. Editorial: Atrial Fibrillation after Coronary Surgery: The Need for an Effective Pharmacological Prophylaxis
  447. Hypertension and Prevention of Diastolic Heart Failure in the Aging Population
  448. Heart function disturbances in chronic kidney disease – echocardiographic indices
  449. Assessment of the Relationship between Lipid Parameters and Obesity Indices in Non-Diabetic Obese Patients: A Preliminary Report
  450. Aging and Heart Failure
  451. Markers of increased cardiovascular risk in patients with chronic kidney disease
  452. Heart remodeling induced by adjuvant trastuzumab-containing chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2: A prospective study
  453. Factors influencing post-coronary artery bypass grafting atrial fibrillation episodes
  454. Stanowisko dotyczące postępowania w rodzinnej hipercholesterolemii u dzieci i młodzieży. Stanowisko Forum Ekspertów Lipidowych
  455. Blood Pressure Levels and Stroke: J-curve Phenomenon?
  456. Effect of Atorvastatin on Low-Density Lipoprotein Subpopulations and Comparison Between Indicators of Plasma Atherogenicity
  457. Postępowanie w rodzinnej hipercholesterolemii u dzieci i młodzieży. Stanowisko Forum Ekspertów Lipidowych
  458. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?
  459. Heart failure biomarkers in patients with dilated cardiomyopathy
  460. Prevention of heart failure in older adults may require higher levels of physical activity than needed for other cardiovascular events
  461. Rate-control versus Rhythm-control Strategies and Outcomes in Septuagenarians with Atrial Fibrillation
  462. The effects of statins on blood pressure in normotensive or hypertensive subjects — A meta-analysis of randomized controlled trials
  463. Rationale of Statin Therapy in Septic Patients
  464. Acute Coronary Syndromes in Patients with Chronic Kidney Disease
  465. Statins in patients with chronic kidney disease – an attempt at recommendations
  466. Medication Management of Chronic Heart Failure in Older Adults
  467. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease
  468. Statin Therapy and New-onset Diabetes: Molecular Mechanisms and Clinical Relevance
  469. Letter on ‘Sodium-dependent modulation of systemic and urinary renalase expression and activity in the rat remnant kidney’
  470. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—A meta-analysis of 11 randomized controlled trials involving 21,295 participants
  471. The Knowledge and Awareness of Hypertension Among Patients With Hypertension in Central Poland
  472. New Obesity Indices and Adipokines in Normotensive Patients and Patients With Hypertension
  473. Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum
  474. Statin therapy and new-onset diabetes: an attempt at recommendations
  475. The Role of Fibrate Treatment in Dyslipidemia: An Overview
  476. Anticoagulant Prevention in Patients with Atrial Fibrillation: Alternatives to Vitamin K Antagonists
  477. Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?
  478. PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
  479. Metabolic syndrome and renal disease
  480. The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspective
  481. The risk of atherosclerosis in patients with chronic kidney disease
  482. Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials
  483. Obesity indices and adipokines in non-diabetic obese patients with early stages of chronic kidney disease
  484. Editorial Statin treatment in the elderly: how much do we know?
  485. Effect of methoxy polyethylene glycol-epoetin beta on oxidative stress in predialysis patients with chronic kidney disease
  486. State of the art paper Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology
  487. Highlights of the mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology
  488. The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy – 5-year follow-up
  489. State of the art paper Treatment of non-ST-elevation myocardial infarction and ST-elevation myocardial infarction in patients with chronic kidney disease
  490. Predictors of Insulin Resistance in Patients With Obesity
  491. Prevention of sudden cardiac death in patients with chronic kidney disease
  492. Blood Pressure J-Curve: Current Concepts
  493. Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?
  494. Renalase, Hypertension, and Kidney — The Discussion Continues
  495. An update on biomarkers of heart failure in hypertensive patients
  496. Observations on Degenerative Changes Within the Optic Nerve in Patients With Primary Open Glaucoma and Arterial Hypertension: 6-Month Follow-Up
  497. Lipids, Blood Pressure, Kidney-what was New in 2012?
  498. Statins and the Risk of Diabetes: The Debate
  499. Statin use and risk of diabetes mellitus in postmenopausal women
  500. The meaning of hypokalemia in heart failure
  501. Preoperative Statin Therapy Is Not Associated With a Decrease in the Incidence of Delirium After Cardiac Operations
  502. Hypertension therapy in the older adults—do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly
  503. Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults
  504. Hypertension and kidney disease
  505. Polish Lipid Association – A strong response to the problem of lipid disorders in Poland and Central and Eastern Europe
  506. Right ventricular ejection fraction <20% is an independent predictor of mortality but not of hospitalization in older systolic heart failure patients
  507. Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 – a prospective study
  508. Editorial Lipid-lowering therapies and achievement of LDL-cholesterol targets
  509. Editorial The effects of statins on blood pressure: current knowledge and future perspectives
  510. Association between heart rate at rest and myocardial perfusion in patients with acute myocardial infarction undergoing cardiac rehabilitation – a pilot study
  511. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels
  512. Imbalance between pro-angiogenic and anti-angiogenic factors in rheumatic and mixomatous mitral valves
  513. Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly
  514. Left atrial size in hypertension and stroke
  515. Statins – Do we really know all mechanisms of action of this group of drugs?
  516. What is the risk of hyperkalaemia in heart failure?
  517. Dronedarone: An overview
  518. Correlation of the severity of diabetic retinopathy and the heart muscle perfusion in patients with type 2 diabetes
  519. Ventricular Assist Device – How to Obtain Optimal Benefits?
  520. What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist?
  521. Gender Differences in the Treatment of Ischemic Heart Disease
  522. Relation of Baseline Systolic Blood Pressure and Long-Term Outcomes in Ambulatory Patients With Chronic Mild to Moderate Heart Failure
  523. Reply to Preoperative n-3 Polyunsatured Fatty Acids Do Not Reduce Postoperative Atrial Fibrillation in Cardiac Surgery, by Takagi I. and Umemoto T
  524. Malignancy-Associated Dyslipidemia
  525. The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe
  526. Statins and dilated cardiomyopathy: do we have enough data?
  527. Erythropoietin update 2011
  528. State of the art papers Lipids, blood pressure, kidney – what was new in 2011?
  529. Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease
  530. Optimal Timing of Discontinuation of Clopidogrel and Risk of Blood Transfusion After Coronary Surgery
  531. Prognostic value of plasma N-terminal pro-B-type natriuretic peptide concentration in patients with normal and impaired left ventricular systolic function undergoing surgery for abdominal aortic aneurysm
  532. Relevance of 123 I-BMIPP delayed scintigraphic imaging for patients with angina pectoris – a pilot study
  533. Editorial [Hot topic: Controversies in Hypertension Treatment (Guest Editors: Maciej Banach, Sverre E. Kjeldsen and Krzysztof Narkiewicz)]
  534. Current Place of Beta-Blockers in the Treatment of Hypertension
  535. Clinical Implications of Non-Invasive Measurement of Central Aortic Blood Pressure
  536. The Use of DSM-IV and ICD-10 Criteria and Diagnostic Scales for Delirium Among Cardiac Surgery Patients: Results From the IPDACS Study
  537. Current problems in hypertension and nephrology
  538. Statins in patients with chronic kidney disease: why, who and when?
  539. Incidence and predictors of delirium after cardiac surgery: Results from The IPDACS Study
  540. Morphine-mediated alteration of hypertension-related gene expression in human white blood cells and multilineage progenitor cells
  541. Postoperative Atrial Fibrillation - What Do We Really Know?
  542. Takotsubo cardiomyopathy — The current state of knowledge
  543. Angiotensin converting-enzyme inhibitors and candesartan have no effects on atrial fibrillation after cardiac surgery
  544. Impact of Baseline Systolic Blood Pressure on Long-Term Outcomes in Patients With Advanced Chronic Systolic Heart Failure (Insights from the BEST Trial)
  545. Levosimendan - a calcium sensitising agent with potential anti-arrhythmic properties
  546. Preoperative n-3 Polyunsatured Fatty Acids Are Associated With a Decrease in the Incidence of Early Atrial Fibrillation Following Cardiac Surgery
  547. The role of Toll-like receptors in renal diseases
  548. Are Polymorphisms within Endothelial Nitric Oxide Synthase Good Predictors of Coronary Artery Disease
  549. Left atrial and left atrial appendage systolic function in patients with post-myocardial distal blocks
  550. Editorial Are we getting to lipid targets in real life?
  551. Effects of coenzyme Q10 supplementation on activities of selected antioxidative enzymes and lipid peroxidation in hypertensive patients treated with indapamide. A pilot study
  552. Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study
  553. Progression of diabetic retinopathy correlated with muscle perfusion disturbances of the lower limbs, with clinically important diagnostic recommendations
  554. Statin therapy in the elderly: A review
  555. Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis
  556. Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation After Cardiac Surgery
  557. Vernakalant hydrochloride for the treatment of atrial fibrillation
  558. The Role of Polymorphisms Within Paraoxonases (192 Gln/Arg in PON1 and 311Ser/Cys in PON2) in the Modulation of Cardiovascular Risk: A Pilot Study
  559. Natriuretic Peptides in Septic Patients
  560. Predictive factors for endoleaks after thoracic aortic aneurysm endograft repair
  561. Lone atrial fibrillation: what do we know?
  562. Role and significance of statins in the treatment of hypertensive patients
  563. Is Polymorphism Within eNOS Gene Associated With the Late Onset of Myocardial Infarction? A Pilot Study
  564. Percutaneous Coronary Interventions Affect Concentrations of Interleukin 6 and Its Soluble Receptors in Coronary Sinus Blood in Patients With Stable Angina
  565. The Clinical Manifestation of Myocardial Infarction in Elderly Patients
  566. Nephroprotective and clinical potential of statins in dialyzed patients
  567. The mechanisms of atrial fibrillation in hyperthyroidism
  568. Atrial Fibrillation: The New Epidemic of the Ageing World
  569. HSP 70 and atherosclerosis – protector or activator?
  570. Aortic stiffness in diabetes mellitus – association with glutamine and heat shock protein 70 expression: a pilot study based on an experimental rodent model
  571. Arteriovenous Fistula Leading to Severe Tortuosity and Aneurysm Formation
  572. The concentration of uric acid in patients with metabolic syndrome and cardiovascular diseases
  573. Endothelial Dysfunction in Patients with Noncomplicated and Complicated Hypertension
  574. Atrial Fibrillation After Isolated Coronary Surgery Affects Late Survival
  575. The Role of Trimetazidine After Acute Myocardial Infarction
  576. Effects of Atorvastatin on Vascular Intimal Hyperplasia: An Experimental Rodent Model
  577. Detection of infectious agents by polymerase chain reaction in human aortic wall
  578. Papaverine solution improves preservation of saphenous vein grafts used during cardiac surgery
  579. The significance of preoperative atrial fibrillation in patients undergoing cardiac surgery: preoperative atrial fibrillation--still underestimated opponent
  580. Dofetilide for the Prevention of Postoperative Atrial Fibrillation After Coronary Surgery: Is It a Useful Routine Prophylaxis?
  581. Obesity and postoperative atrial fibrillation. Is there no connection?
  582. Statins in the prevention of postoperative atrial fibrillation: Is there really no effect?
  583. Endovascular treatment of mycotic aortic aneurysms
  584. Plasma Total Antioxidant Activity in Comparison With Plasma NO and VEGF Levels in Patients With Metabolic Syndrome
  585. Does Gender Influence the Patency of Infrainguinal Bypass Grafts?
  586. LEFT VENTRICULAR DIASTOLIC DYSFUNCTION IN SUBJECTS WITH METABOLIC SYNDROME
  587. Effect of Cardiovascular Drugs on Adenosine Deaminase Activity
  588. Relation Between Postoperative Mortality and Atrial Fibrillation Before Surgical Revascularization - 3-Year Follow-Up
  589. Letter by Banach et al Regarding Article, "Postoperative Treatment With Carvedilol, a β-Adrenergic Blocker, Prevents Paroxysmal Atrial Fibrillation After Coronary Artery Bypass Grafting"
  590. Natriuretic peptides in cardiovascular diseases
  591. Carvedilol modifies antioxidant status of patients with stable angina
  592. Clinical Utility and Use of DSM–IV and ICD–10 Criteria and The Memorial Delirium Assessment Scale in Establishing a Diagnosis of Delirium After Cardiac Surgery
  593. Comparison of Transperitoneal and Retroperitoneal Approaches in Abdominal Aortic Surgery
  594. eComment: The anastomosis between aorta and extension conduit of the pulmonary artery
  595. Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation
  596. Predictors of paroxysmal atrial fibrillation in patients undergoing aortic valve replacement
  597. Evaluation of selected parameters of the antioxidative system in patients with type 2 diabetes in different periods of metabolic compensation
  598. Echocardiographic Evaluation of the Left Atrium and Left Atrial Appendage Function in Patients with Atrial Septum Aneurysm - Implications for Thromboembolic Complications
  599. Plasma Endothelin-1 Levels in Septic Patients
  600. 92 Low BMI as an independent risk factor of death in patients with severe heart failure subjected to aortic valve replacement
  601. Atrial and Brain Natriuretic Peptide and Endothelin-1 Concentration in Patients with Idiopathic Arterial Hypertension: The Dependence on the Selected Morphological Parameters
  602. N-terminal brain natriuretic propeptide levels correlate with procalcitonin and C-reactive protein levels in septic patients
  603. Preoperative predictors of delirium after cardiac surgery: a preliminary study
  604. Increased whole blood chemiluminescence in patients with chronic renal failure independent of hemodialysis treatment
  605. N-TERMINAL BRAIN NATRIURETIC PROPEPTIDE LEVELS CORRELATE WITH PROCALCITONIN AND C-REACTIVE PROTEIN LEVELS IN SEPTIC PATIENTS
  606. Neutrophil Superoxide Anion Generation During Atorvastatin and Fluvastatin Therapy Used in Coronary Heart Disease Primary Prevention
  607. Risk Factors for Atrial Fibrillation in Adult Patients in Long-Term Observation Following Surgical Closure of Atrial Septal Defect Type II
  608. TNF-α priming effect on polymorphonuclear leukocyte reactive oxygen species generation and adhesion molecule expression in hemodialyzed patients
  609. P3-49
  610. Risk Factors of Atrial Fibrillation Following Coronary Artery Bypass Grafting
  611. Increased Levels of Soluble TNF-α Receptors and Cellular Adhesion Molecules in Patients Undergoing Bioincompatible Hemodialysis